SEC 13F Intelligence

Krensavage Asset Management, LLC / SUPN

Krensavage Asset Management, LLC’s Supernus Pharmaceuticals Position

Does Krensavage Asset Management, LLC own Supernus Pharmaceuticals (SUPN)? Yes — 280.7K shares worth $15M (+5.67% of its 13F portfolio) as of Q1 2026, down from 313.5K shares the prior filed quarter.

Position Value
$15M
Q1 2026
Shares
280.7K
% of Portfolio
+5.67%
Quarters Held
5
currently held

Position History SUPN

Reported value by quarter
Q1 ’25: $14MQ1 ’25Q2 ’25: $15MQ2 ’25Q3 ’25: $17MQ3 ’25Q4 ’25: $16MQ4 ’25Q1 ’26: $15MQ1 ’26filingsflow.com
QuarterSharesValue% of Portfolio
Q1 2026280.7K$15M+5.67%
Q4 2025313.5K$16M+5.50%
Q3 2025363.5K$17M+7.40%
Q2 2025472.4K$15M+7.88%
Q1 2025432.0K$14M+7.82%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Krensavage Asset Management, LLC’s full portfolio or all institutional holders of SUPN.